Oncology

Top news of the week from Specialty Pharmacy Times.

Centers for Medicare & Medicaid Services proposed national coverage determination of the FoundationOne CDx test.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.

The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.

Rising cancer drug costs have become inreasingly worrisome for patients and health care providers. Despite the entry of competitors in the market, treatment costs continue to climb over time, according to a study recently published by the Journal of Clinical Oncology.

In 2017, lung cancer is projected to be the second most prevalent type of cancer in the United States, with about 222,500 new cases and is estimated to still be the leading cause of cancer-related death, with 155,870 deaths.

A new system allows researchers to test multiple drug combinations in cultured cancer stem cells from patients.

High oncology drug costs could impact adherence to cancer treatment.

Mastectomy for early-stage breast cancer increases the risk of missing more than 1 month of work.

Novel predictive model harnesses technology to diagnose ovarian cancer more accurately than ultrasound.

Glecaprevir and pibrentasvir (Mavyret) shows efficacy across hepatitis C genotypes.

Elvin Montanez, PharmD, chief operations officer at BioPlus Specialty Pharmacy, discusses how to improve patient outcomes and decrease oncology spend.

A look at last week's top stories in the world of pharmacy.

Combining cancer drugs may help prevent drug resistance.

A look at last week's top stories in the world of pharmacy.

Multiple mutations may work together to develop drug-resistant non-small cell lung cancer.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

A cancer diagnosis in young patients can cause post-traumatic stress disorder that can persist long afterwards.

Medicare sequester cuts could restrict access to care for seniors with cancer.

Doubling Medicare sequester cuts could reduce access to lower-cost cancer treatment.

Only 15% of patients with a 20% to 24% risk of breast cancer received a recommended MRI screening.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

Exposure to ammonia found to amplify breast cancer cell proliferation.

Nine other countries are on track to eliminate the hepatitis C virus by 2030.

Top news of the week from Specialty Pharmacy Times.